Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapeutic regimes including metastatic treatment, adjuvant treatment, neoadjuvant treatment, or combination therapy were equally effective in reducing CTC positivity and the chance of disease progression [151].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another study, involving 6712 breast cancer patients showed a decrease in the number of CTCs only in human epidermal growth factor receptor 2 (HER2+) or HER2- patients but not in the triple-negative ones and nor in patients who underwent surgery.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [151]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Smerage, J. B., Barlow, W. E., Hortobagyi, G. N., Winer, E. P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A. F., O'Rourke, M. A., Lew, D. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2561 · Cited by 648
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615
Müller, V., Stahmann, N., Riethdorf, S., Rau, T., Zabel, T., Goetz, A., Jänicke, F., & Pantel, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2469 · Cited by 403
Pierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Janni, W. J., Rack, B., Terstappen, L. W. M. M., Pierga, J.-Y., Taran, F.-A., Fehm, T., Hall, C., de Groot, M. R., Bidard, F.-C., Friedl, T. W. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1603 · Cited by 363
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Kalbakis, K., Agelaki, S., Stathopoulos, E. N., Chlouverakis, G., Lianidou, E., Kakolyris, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0497 · Cited by 238
Liu, Z., Fusi, A., Klopocki, E., Schmittel, A., Tinhofer, I., Nonnenmacher, A., & Keilholz, U. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-70 · Cited by 189
Bidard, F., Mathiot, C., Degeorges, A., Étienne-Grimaldi, M.-C., Delva, R., Pivot, X. B., Veyret, C., Bergougnoux, L., de Crémoux, P., Milano, G. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq052 · Cited by 160
Nolé, F., Munzone, E., Zorzino, L., Minchella, I., Salvatici, M., Botteri, E., Medici, M., Verri, E., Adamoli, L., Rotmensz, N., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm558 · Cited by 159
Clinical and biological significance of circulating tumor cells in cancer
Masuda, T., Hayashi, N., Iguchi, T., Ito, S., Eguchi, H., & Mimori, K. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.010 · Cited by 159
Biomarkers characterization of circulating tumour cells in breast cancer patients
Nadal, R., Fernandez, A., Sánchez‐Rovira, P., Salido, M., Rodríguez, M., García-Puche, J. L., Macià, M., Corominas, J. M., Delgado‐Rodríguez, M., González-Herrera, L., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3180 · Cited by 107
Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer
Smerage, J. B., Budd, G. T., Doyle, G. V., Brown, M., Paoletti, C., Muñiz, M. C., Miller, M. C., Repollet, M., Chianese, D. A., Connelly, M. C., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.013 · Cited by 103
Bidard, F., Hajage, D., Bachelot, T., Delaloge, S., Brain, E. G. C., Campone, M., Cottu, P. H., Beuzeboc, P., Rolland, E., Mathiot, C., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3114 · Cited by 83
Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer
Hayashi, N., Nakamura, S., Tokuda, Y., Shimoda, Y., Yagata, H., Yoshida, A., Ota, H., Hortobágyi, G. N., Cristofanilli, M., & Ueno, N. T. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0260-0 · Cited by 83
Hartkopf, A. D., Wagner, P., Wallwiener, D. R., Fehm, T. N., & Rothmund, R. (2011) · PubMed · Cited by 79
Kasimir‐Bauer, S., Bittner, A., König, L., Reiter, K., Keller, T., Kimmig, R., & Hoffmann, O. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0679-3 · Cited by 78
Wallwiener, M., Riethdorf, S., Hartkopf, A. D., Modugno, C., Nees, J., Madhavan, D., Sprick, M. R., Schott, S., Domschke, C., Baccelli, I., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-512 · Cited by 77
Peeters, D. J. E., van Dam, P.-J., den Eynden, G. G. V., Rutten, A., Wuyts, H., Pouillon, L., Peeters, M., Pauwels, P., Laere, S. V., van Dam, P. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.743 · Cited by 76
Beije, N., Jager, A., & Sleijfer, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.008 · Cited by 71
Pierga, J., Petit, T., Lévy, C., Ferrero, J.-M., Campone, M., Gligorov, J., Lerebours, F., Roche, H. H., Bachelot, T., Charafe‐Jauffret, E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1705 · Cited by 70
Mego, M., Gao, H., Lee, B.-N., Cohen, E. N., Tin, S., Giordano, A., Wu, Q., Liu, P., Nieto, Y. L., Champlin, R. E., et al. (2012) · Journal of Cancer · doi:10.7150/jca.5111 · Cited by 68
Circulating tumor cells in the diagnosis and management of pancreatic cancer
Cen, P., Ni, X., Yang, J., Graham, D. Y., & Li, M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.05.007 · Cited by 65
Circulating tumor cells before and during follow-up after breast cancer surgery
van Dalum, G., STAM, G. J. V. D., Tibbe, A. G. J., Franken, B., MASTBOOM, W. J. B., VERMES, I., de Groot, M. R., & Terstappen, L. W. M. M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2694 · Cited by 65
Jiang, Z., Cristofanilli, M., Shao, Z., Tong, Z., Song, E. W., Wang, X.-J., Liao, N., Hu, X., Liu, Y., Wang, Y., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt246 · Cited by 60
Self-citationBidard, F., Belin, L., Delaloge, S., Lerebours, F., Ngô, C., Reyal, F., Alran, S., Giacchetti, S., Marty, M. E., Lebofsky, R., et al. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/130470 · Cited by 59
International study on inter-reader variability for circulating tumor cells in breast cancer
Ignatiadis, M., Riethdorf, S., Bidard, F., Vaucher, I., Khazour, M., Rothé, F., Metallo, J., Rouas, G., Payne, R., Coombes, R. C., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3647 · Cited by 58
Clinical application of circulating tumor cells in breast cancer
Broersen, L. H. A., van Pelt, G. W., Tollenaar, R. A. �. �., & Mesker, W. E. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0160-6 · Cited by 55
Reinholz, M. M., Kitzmann, K. A., Tenner, K., Hillman, D. W., Dueck, A. C., Hobday, T. J., Northfelt, D., Moreno‐Aspitia, A., Roy, V., LaPlant, B. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0981 · Cited by 55
Pierga, J., Bidard, F., Cropet, C., Tresca, P., Dalenc, F., Romieu, G., Campone, M., Aït-Oukhatar, C. M., Rhun, É. L., Gonçalvès, A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt348 · Cited by 52
Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Magbanua, M. J. M., Carey, L., DeLuca, A. N., Hwang, J., Scott, J. H., Rimawi, M. F., Mayer, E. L., Marcom, P. K., Liu, M., Esteva, F. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1948 · Cited by 44
Martín, M., Custodio, S., Casas, M.-L. M., García-Sáenz, J.-Á., Torre, J.-C., Bellón-Cano, J.-M., López-Tarruella, S., Vidaurreta-Lazaro, M., Orden, V., Jerez, Y., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0479 · Cited by 41
Roop, R. P., Naughton, M. J., Poznak, C. H. V., Schneider, J. G., Lammers, P. E., Pluard, T., Johnson, F. C., Eby, C. S., & Weilbaecher, K. N. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.006 · Cited by 40
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Adams, D. L., Adams, D. K., Stefansson, S., Haudenschild, C., Martin, S. S., Charpentier, M., Chumsri, S., Cristofanilli, M., Tang, C.-M., & Alpaugh, R. K. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0706-4 · Cited by 40
Azim, H. A., Rothé, F., Aura, C. M., Bavington, M., Maetens, M., Rouas, G., Gebhart, G., Cenzano, C. G., Eidtmann, H., Baselga, J. M., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.08.014 · Cited by 39
Circulating tumor cells in early breast cancer: A connection with vascular invasion
Maltoni, R., Fici, P., Amadori, D., Gallerani, G., Cocchi, C., Zoli, M., Rocca, A., Cecconetto, L., Folli, S., Scarpi, E., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.020 · Cited by 39
Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy
SERRANO, M. J., ROVIRA, P. S., MARTÍNEZ-ZUBIAURRE, I., RODRIGUEZ, M. D., FERNÁNDEZ, M., & LORENTE, J. A. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.540 · Cited by 37
Serrano, M. J., Sánchez‐Rovira, P., Delgado‐Rodríguez, M., & Gaforio, J. J. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7834 · Cited by 36
CTCs in early breast cancer: A path worth taking
Maltoni, R., Gallerani, G., Fici, P., Rocca, A., & Fabbri, F. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.051 · Cited by 34
Xenidis, N., Perraki, M., Apostolaki, S., Agelaki, S., Kalbakis, K., Vardakis, N., Kalykaki, A., Xyrafas, A., Kakolyris, S., Mavroudis, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.597 · Cited by 33
Mikulová, V., Čabiňaková, M., Janatková, I., Mestek, O., Zima, T., & Tesařová, P. (2013) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2013.864784 · Cited by 26
Wang, H.-Y., Ahn, S., Kim, S., Park, S., Jung, D., Park, S., Han, H., Sohn, J., Kim, S. I., & Lee, H. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0798-3 · Cited by 25
Barnadas, A., Manso, L., de la Piedra, C., Meseguer, C., Crespo, C., Gómez, P., Calvo, L., Martinez, P., Ruíz‐Borrego, M., Perelló, A., et al. (2014) · Bone · doi:10.1016/j.bone.2014.07.036 · Cited by 18
Daskalakis, M., Mavroudis, D., Sanidas, E. E., Apostolaki, S., Askoxylakis, I., de Bree, E., Georgoulias, V., & Melissas, J. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.02.003 · Cited by 16
Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
Ušiaková, Z., Mikulová, V., Pintérová, D., Brychta, M., Valchář, J., Kubecova, M., Tesařová, P., Bobek, V., & Kološtová, K. (2014) · PubMed · Cited by 14
Tokudome, N., Ito, Y., Takahashi, S., Kobayashi, K., Taira, S., Tsutsumi, C., Oto, M., Oba, M., Inoue, K., Kuwayama, A., et al. (2011) · Breast Cancer · doi:10.1007/s12282-011-0259-4 · Cited by 14
Tryfonidis, K., Boukovinas, I., Xenidis, N., Christophyllakis, C., Papakotoulas, P., Politaki, E., Malamos, N. A., Polyzos, A., Kakolyris, S., Georgoulias, V., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.08.017 · Cited by 11
Detection of Circulating Tumor Cells in Breast Cancer Patients: Prognostic Predictive Role
Türker, İ., Üyetürk, Ü., Sönmez, Ö., Öksüzoğlu, B. Ç., Helvacı, K., Arslan, Ü. Y., Budakoğlu, B., Alkış, N., Aksoy, S., & Zengin, N. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.3.1601 · Cited by 10
CAUSES OF DEATH IN PATIENTS WITH STAGE 0-II BREAST CANCER.
Ursaru, M., Jari, I., Naum, A. S., Scripcariu, V., & Negru, D. (2015) · The Medical-Surgical Journal · Cited by 10
Лавров, А. В., Zubtsova, Z. I., Zubtsov, D. A., Фролова, М. А., Ignatova, E., Skrypnikova, M., Малышева, Е. В., Legchenko, E., Петровский, А. В., Utyashev, I. A., et al. (2014) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-014-2514-0 · Cited by 7
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Zhang, J., Yao, Q., Chen, J., Wang, Y., Wang, H., Fan, Q., Ling, R., Yi, J., & Wang, L. (2015) · Genetics and Molecular Research · doi:10.4238/2015.march.20.20 · Cited by 7
Self-citationBoutrus, R. R., Raad, R. F. A., Kuter, I., Ancukiewicz, M., Roberts, L., Solomon, N. A., Ngo, T., Borick, H., Ryan, P. D., Moy, B., et al. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9580 · Cited by 7
Čabiňaková, M., Mikulová, V., Malíčková, K., Vrána, D., Pavlista, D., Petruzelka, L. B., Zima, T., & Tesařová, P. (2015) · Neoplasma · doi:10.4149/neo_2015_031 · Cited by 6
Horn, P. B., Jakobsen, E. H., Madsen, J. S., & Brandslund, I. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.09.010 · Cited by 6
Bidard, F., Ligthart, S. T., Bachelot, T., Delaloge, S., Brain, E. G. C., Campone, M., Viens, P., Pierga, J., & Terstappen, L. W. M. M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds040 · Cited by 3
Mathiesen, R. R., Borgen, E., Sætersdal, A. B., Fangberget, A., Schirmer, C. B., Stav, I., Fagerland, M. W., Wist, E., Engebråten, O., & Naume, B. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-p1-08-21 · Cited by 3
Bian, L., Liu, Y., Wang, T., Zhang, S., Shao, Z., Tong, Z., Song, E., Wang, X., Liao, N., & Jiang, Z. (2014) · PubMed · Cited by 3
Neugebauer, J. K., Rack, B. K., Jaeger, B. A. S., Andergassen, U., Pestka, A., Fasching, P. A., Friedl, T. W. P., Mouarrawy, D., Clemens, M., Ziemendorff, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.11043 · Cited by 3
Pierga, J., Hajage, D., Bachelot, T., Delaloge, S., Brain, E. G. C., Campone, M., Asselain, B. J. R., Mathiot, C., & Bidard, F. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-3208 · Cited by 2
Cristofanilli, M., Giorgi, U. D., ROHREN, E. M., Ueno, N. T., Miller, C., Doyle, G. N., Jackson, S. A., Andreopoulou, E., Handy, B. C., Reuben, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-6052 · Cited by 1
Joulain, F., Iqbal, S. U., Diamand, F., Cutsem, E. V., Hoyle, M., & Allegra, C. J. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(19)66516-6 · Cited by 1
A phase II clinical trial of neoadjuvant therapy with zoledronic acid for operable breast cancer.
Nakayama, Y., Takahashi, S., & Ito, Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e22027 · Cited by 1
Circulating tumor cells (CTCs) and epithelial mesenchymal transition (EMT) in primary breast cancer.
Karaba, M., Mego, M., Minárik, G., Benca, J., Sedláčková, T., Manasova, D., Sieberova, G., Hlavata, Z., Jurik, A., Minařík, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e22023 · Cited by 1
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Therapeutic regimes including metastatic treatment, adjuvant treatment, neoadjuvant treatment, or combination therapy were equally effective in reducing CTC positivity and the chance of disease progression [151].”
BackgroundLiquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., & Silvestris, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918794630 · Cited by 423
Clinical applications of the CellSearch platform in cancer patients
Riethdorf, S., O'Flaherty, L., Hille, C., & Pantel, K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.011 · Cited by 275
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
Russano, M., Napolitano, A., Ribelli, G., Iuliani, M., Simonetti, S., Citarella, F., Pantano, F., Dell’Aquila, E., Anesi, C., Silvestris, N., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01601-2 · Cited by 260
Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring
Martins, I., Ribeiro, I. P., Jorge, J., Gonçalves, A. C., Sarmento-Ribeiro, A. B., Melo, J. B., & Carreira, I. M. (2021) · Genes · doi:10.3390/genes12030349 · Cited by 205
“Given that these cells are closely involved in the metastatic process, monitoring them might help predict the patients’ post-treatment outcomes and risk of metastasis [88,89].”
Background
Metadata
- Authors
- Yan, W.-T., Cui, X., Chen, Q., Li, Y.-F., Cui, Y.-H., Wang, Y., & Jiang, J.
- Affiliations
- Army Medical University (CN)
- Corresponding author
- Jiang, Jun
- Venue
- Scientific Reports
- Published
- 2017-03-24
- Volume
- 7
- Issue
- 1
- Pages
- 43464-43464
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5364512
- OpenAlex
- W2599986806
- Cited by
- 113
- References
- 64
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 16 · 2022: 14 · 2021: 20 · 2020: 20 · 2019: 19 · 2018: 12 · 2017: 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- circulating tumor cells, breast cancer, treatment response monitoring, neoadjuvant therapy, adjuvant therapy, metastatic breast cancer, HER2-positive breast cancer, triple-negative breast cancer, disease progression, overall survival, progression-free survival
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Monitoring, Physiologic, Neoplastic Cells, Circulating, Prognosis, Risk Factors, Biomarkers, Tumor, Gene Expression, Odds Ratio, Survival Analysis, Disease Progression, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.